remifentanil torrex 1 mg por oldatos injekcióhoz vagy infúzióhoz való koncentrátumhoz
chiesi pharmaceuticals gmbh - remifentanil -
remifentanil torrex 2 mg por oldatos injekcióhoz vagy infúzióhoz való koncentrátumhoz
chiesi pharmaceuticals gmbh - remifentanil -
remifentanil torrex 5 mg por oldatos injekcióhoz vagy infúzióhoz való koncentrátumhoz
chiesi pharmaceuticals gmbh - remifentanil -
ropivakain torrex 2 mg/ml oldatos infúzió
chiesi pharmaceuticals gmbh - ropivacaine -
ropivakain torrex 2 mg/ml oldatos injekció
chiesi pharmaceuticals gmbh - ropivacaine -
ropivakain torrex 7,5 mg/ml oldatos injekció
chiesi pharmaceuticals gmbh - ropivacaine -
ropivakain torrex 10 mg/ml oldatos injekció
chiesi pharmaceuticals gmbh - ropivacaine -
foster nexthaler 200 mikrogramm/6 mikrogramm/adag inhalációs por
chiesi pharmaceuticals gmbh - beclometasone; formoterol -
foster nexthaler 100 mikrogramm/6 mikrogramm/adag inhalációs por
chiesi pharmaceuticals gmbh - beclometasone; formoterol -
kymriah
novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - egyéb daganatellenes szerek - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.